Hemodynamic effect of amrinone depends on pretreatment vascular resistance in patients with evolving congestive heart failure: correlation between vascular resistance and neurohormonal activity.
We investigated the hemodynamic effects of amrinone and assessed its effects on neurohormonal factors in 15 patients with evolving congestive heart failure with various origins. We serially determined the pulmonary and systemic vascular-resistance indices after amrinone infusion and examined the relation between changes in hemodynamic parameters and changes in concentrations of norepinephrine, atrial natriuretic peptide, angiotensin II, and endothelin-1 in the pulmonary capillary wedge region (PCWR) and in the peripheral veins. Amrinone significantly reduced pulmonary vascular-resistance index (PVRI; Wood x m2) in patients with high PVRI (> or =15) before the infusion, significantly reduced systemic vascular-resistance index (SVRI; Wood x m2) in patients with high SVRI (> or =50) before the infusion, and had little effect on vascular resistances in patients with low PVRI (<15) and low SVRI (<50). The reduction in PVRI was correlated with the reduction in the endothelin-1 level (r = 0.75) in the PCWR, and the reduction in SVRI with norepinephrine level (r = 0.70) in the peripheral veins. The angiotensin II level did not change throughout the study. These findings suggest that amrinone had selective hemodynamic effects on pulmonary and systemic circulations with neurohormonal effects, according to PVRI and SVRI before infusion.
Sasaki
T
T
Division of Cardiology, National Cardiovascular Center, Suita-city, Osaka, Japan.
Tomimoto
S
S
Noguchi
T
T
Baba
T
T
Komamura
K
K
Ohmori
F
F
Miyatake
K
K
D000368:Aged; D000676:Amrinone / Q000627:therapeutic use*; D000804:Angiotensin II / Q000378:metabolism; D015415:Biomarkers; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D019332:Endothelin-1 / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000378:metabolism* / Q000503:physiopathology / Q000517:prevention & control*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D013223:Statistics as Topic; D014655:Vascular Resistance / Q000187:drug effects* / Q000502:physiology
D015415:Biomarkers; D002316:Cardiotonic Agents; D019332:Endothelin-1; D000804:Angiotensin II; D000676:Amrinone; D009638:Norepinephrine